Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: The LOGICA study

Annals of the Rheumatic Diseases

Volumn 69, Issue 8, 2010, Pages 1453-1458

  Lanas, Angel ^a   Tornero, Jesús ^b   Zamorano, José Luis ^c  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CELECOXIB; CHONDROITIN; CODEINE; DEXIBUPROFEN; DEXKETOPROFEN; DIACETYLRHEIN; DICLOFENAC; DIPYRONE; ETORICOXIB; GLUCOSAMINE; IBUPROFEN; INDOMETACIN; LORNOXICAM; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; TRAMADOL;

AGED; ARTICLE; CARDIOVASCULAR RISK; FEMALE; GASTROINTESTINAL TRACT; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; GASTROINTESTINAL DISEASES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER; RISK ASSESSMENT; SPAIN;

EID: 77955457028     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.123166     Document Type: Article

References (33)

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343-55.
2. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
3. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002;23:S24-30;discussion:S31-4.
4. Lanas A. Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Options Gastroenterol 2006;9:147-56.
5. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28.
6. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
7. García Rodríguez LA, González-Pérez A. Long-term use of non-steroidal antiinfl ammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3:17.
8. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74.
9. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
10. FDA. Safety Alerts for Human Medical Products. COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs NSAIDs. 2005. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm151410.htm.
11. EMEA. EMEA Press Release: European Medicines Agency Review Concludes Positive Benefit-risk Balance for Non-selective NSAIDs. CHMP 24 october 2006. Doc. Ref. EMEA/413136/2006. http://www.emea.europa.eu/pdfs/human/press/pr/ 41313606.pdf (Accessed 3 September 2009).
12. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007;369:1580-1.
13. Conroy RM, Pyorala K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
14. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2007;24:1601-10.
15. Muller-Nordhorn J, Binting S, Roll S, et al. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008;29:1316-26.
16. Lanas A, Martin-Mola E, Ponce J, et al. Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents. Gastroenterol Hepatol 2003;26:485-502. (Pubitemid 37328391)
17. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
18. Tannenbaum H, Peloso PM, Russell AS, et al. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000;7(Suppl A): 4A-16A.
19. Thompson PW, Tee L, McBride J, et al. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events. Rheumatology (Oxford) 2005;44:1308-10.
20. Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006;38:415-28.
21. Laine L, Smith R, Min K, et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006;24:751-67.
22. Lanas A, García-Rodríguez LA, Arroyo MT, et al; Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal antiinfl ammatory drugs, aspirin and combinations. Gut 2007;55:1731-8.
23. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006;4:22.
24. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19:1051-61.
25. Sebaldt RJ, Petrie A, Goldsmith CH, et al. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J Manag Care 2004;10:742-50.
26. Tannenbaum H, Bombardier C, Davis P, et al; Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. J Rheumatol 2006;33:140-57.
27. NICE. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults: Royal College of Physicians, 2008. Clinical Guideline number 59. http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf (Accessed 3 September 2009).
28. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81.
29. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-62.
30. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7.
31. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87.
32. Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3:98-101.
33. Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79.